Sermorelin — the GHRH (1-29) research peptide and its regulatory history

Sermorelin is a 29-amino-acid synthetic peptide that reproduces the first 29 residues of native human growth-hormone-releasing hormone (GHRH 1-29). The 29-residue fragment retains the receptor-binding activity of full-length GHRH but with no further structural modification. The molecule was approved historically for paediatric GH-deficiency diagnostic use and was withdrawn from the US market in 2008; research-grade Sermorelin remains in use for academic and grey-research protocols investigating acute pulsatile GH release.

What Sermorelin actually is

Sermorelin is the synthetic acetate salt of the 29-amino-acid fragment representing residues 1-29 of native human GHRH. The sequence (Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg) reproduces the receptor-binding region of full-length 44-residue GHRH. No structural modifications are added — Sermorelin is, in effect, native GHRH truncated.

Molecular weight is approximately 3,358 Da. The compound is manufactured by solid-phase peptide synthesis. As the foundational structure of the GHRH-analogue class, Sermorelin is the comparator against which Tesamorelin, Modified GRF (1-29), and CJC-1295 are typically measured.

Receptor mechanism

Sermorelin binds the pituitary GHRH receptor (GHRH-R) with affinity comparable to native full-length GHRH. The receptor is a G-protein-coupled receptor of the secretin family; agonism triggers G(s)-coupled cAMP elevation in pituitary somatotroph cells, driving growth-hormone release. The receptor pharmacology is shared across the entire GHRH-analogue class — Sermorelin, Tesamorelin, Modified GRF, CJC-1295 all bind the same receptor with comparable affinity.

The pharmacological feature that separates Sermorelin from the rest of the class is its plasma half-life — approximately 12 minutes, only marginally longer than native GHRH. The short half-life is because Sermorelin retains the native N-terminal tyrosine that DPP-IV cleaves rapidly. Tesamorelin and Modified GRF (1-29) modify the N-terminal region to block DPP-IV access and extend plasma half-life to ~26-38 minutes.

Regulatory history

Sermorelin received FDA approval in 1997 for paediatric GH-deficiency diagnostic use. The diagnostic protocol used a single subcutaneous dose followed by serial GH-axis sampling — exactly the use case the short half-life enables. The acute GH-release peak following Sermorelin administration was a reliable indicator of pituitary GH-axis competence.

The molecule was voluntarily withdrawn from the US market in 2008 by the original manufacturer, primarily for commercial reasons (the diagnostic-use volume was small, and newer GH-deficiency diagnostic protocols had emerged). The withdrawal was not safety-driven; the safety profile in published clinical use was clean. Research-grade Sermorelin remains available for non-clinical investigation through laboratory suppliers; the prescription-medicine status no longer applies in the US market.

Honest take: Sermorelin’s market withdrawal is a commercial-history fact, not a safety signal. The molecule is still a clean, well-characterised GHRH analogue. The research-peptide market continues to use it for acute pituitary-axis questions where the short half-life is an advantage rather than a limitation.

Current research-use protocols

Sermorelin remains in active research use for three protocol categories:

• Acute pituitary GH-axis diagnostic research. The short half-life produces a single sharp GH pulse, useful for assessing pituitary GH-axis competence in research populations. Compared to Tesamorelin or CJC-1295 with DAC, the acute-pulse pattern is cleaner.
• Chronic-administration research with daily-or-twice-daily dosing. Some research protocols use Sermorelin with twice-daily or thrice-daily administration to compensate for the short half-life. The frequent-dosing protocols are less common than the Tesamorelin daily-dose standard.
• Comparator-arm in head-to-head GHRH-analogue research. Studies comparing newer GHRH analogues against Sermorelin as the native-GHRH comparator are published periodically.

UAE research-supply landscape

Sermorelin is supplied in the UAE as lyophilised research-grade powder. Vial sizes commonly available range from 2 mg to 15 mg per vial. The molecule is among the simpler peptides in the GHRH-analogue class to synthesise (29 residues, no further modification), which makes supply more widely available and the purity-control practice less differentiating between suppliers than for Tesamorelin or CJC-1295.

Quality verification: third-party HPLC purity ≥98%, mass-spectrometry confirmation of the parent ion (~3,358 Da), batch-traceable certificate of analysis. Reconstitution with bacteriostatic water; refrigerated re-entry window ~28 days.

Open research questions

• Whether Sermorelin’s short half-life pulsatile GH-release pattern produces meaningfully different downstream IGF-1 or visceral-adipose effects vs Tesamorelin at equivalent total weekly GHRH-axis exposure. The two molecules have not been directly compared in head-to-head trials at equivalent doses.
• Whether the receptor desensitisation pattern with chronic frequent Sermorelin dosing differs from the once-daily Tesamorelin profile.
• The published in-vivo human data on chronic Sermorelin administration in adult research populations is thin; most adult-use evidence is observational or single-trial.

Further reading

• Sermorelin vs Tesamorelin — focused comparison.
• Sermorelin dosing in research protocols.
• Sermorelin regulatory history — 1997 approval to 2008 withdrawal.
• Tesamorelin parent overview.
• Tesamorelin vs the wider GHRH-analogue class.
• CJC-1295 + Ipamorelin research overview.

Last reviewed 2 June 2026. Editorial inbox: info@uaewellnesslab.com.